Merck (NYSE:MRK) is expected to report Q1 earnings before the market open on Friday, April 27 with a conference call scheduled for 8am ET.
Analysts are looking for EPS of 98c on revenue of $11.82B. The consensus range is 95c-99c for EPS, and $11.5B-$12.09B for revenue, according to First Call. Positive catalysts for the drug giant should continue to be seen coming from its Januvia/Janumet franchise, animal health sales and newer drugs like Victrelis.Tight cost controls should also continue to add to the bottom line. Headwinds for Merck maybe seen from decreased Remicade sales and compromised global spending from austerity measures.